Patents Assigned to Acadia Pharmaceuticals Inc.
  • Compounds with activity on muscarinic receptors
    Patent number: 6528529
    Abstract: Compounds and methods are provided for the alleviation or treatment of diseases or conditions in which modification of muscarinic m1 receptor activity has a beneficial effect. In the method, a therapeutically effective amount of a selective muscarinic m1 agonist compound is administered to a patient in need of such treatment.
    Type: Grant
    Filed: July 16, 1999
    Date of Patent: March 4, 2003
    Assignee: Acadia Pharmaceuticals Inc.
    Inventors: Mark Brann, Terri Messier, Erika Currier, Kate Duggento, Tracy Spalding, Mikael Friberg, Niels Skjaerbaek
  • Identification of ligands by selective amplification of cells transfected with receptors
    Patent number: 5955281
    Abstract: The invention is directed to a method for identifying substances acting as ligands for transfected receptors by using transfected markers to measure receptor/ligand interactions.
    Type: Grant
    Filed: November 7, 1997
    Date of Patent: September 21, 1999
    Assignee: Acadia Pharmaceuticals, Inc.
    Inventor: Mark Robert Brann
  • Identification of ligands by selective amplification of cells transfected with receptors
    Patent number: 5912132
    Abstract: The invention is directed to a method for identifying substances acting as ligands for transfected receptors by using transfected markers to measure receptor/ligand interactions.
    Type: Grant
    Filed: October 20, 1997
    Date of Patent: June 15, 1999
    Assignee: Acadia Pharmaceuticals, Inc.
    Inventor: Mark Robert Brann